CA2906694A1 - Peptide compositions - Google Patents

Peptide compositions Download PDF

Info

Publication number
CA2906694A1
CA2906694A1 CA2906694A CA2906694A CA2906694A1 CA 2906694 A1 CA2906694 A1 CA 2906694A1 CA 2906694 A CA2906694 A CA 2906694A CA 2906694 A CA2906694 A CA 2906694A CA 2906694 A1 CA2906694 A1 CA 2906694A1
Authority
CA
Canada
Prior art keywords
arg
phe
cys
trp
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2906694A
Other languages
English (en)
French (fr)
Inventor
Shubh Sharma
Leonardus H. T. Van Der Ploeg
Bart Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhythm Pharmaceuticals Inc
Original Assignee
RHYTHM METABOLIC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RHYTHM METABOLIC Inc filed Critical RHYTHM METABOLIC Inc
Publication of CA2906694A1 publication Critical patent/CA2906694A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2906694A 2013-03-15 2014-03-14 Peptide compositions Pending CA2906694A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
US61/790,469 2013-03-15
PCT/US2014/028590 WO2014144260A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Publications (1)

Publication Number Publication Date
CA2906694A1 true CA2906694A1 (en) 2014-09-18

Family

ID=50588892

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2906694A Pending CA2906694A1 (en) 2013-03-15 2014-03-14 Peptide compositions

Country Status (10)

Country Link
US (4) US10196425B2 (https=)
EP (2) EP2970388B1 (https=)
JP (4) JP6622690B2 (https=)
CN (3) CN105492456B (https=)
AU (5) AU2014227712B2 (https=)
CA (1) CA2906694A1 (https=)
ES (1) ES2693761T3 (https=)
RU (2) RU2020120797A (https=)
TR (1) TR201815173T4 (https=)
WO (1) WO2014144260A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2785889C1 (ru) * 2015-09-30 2022-12-14 Ритм Фармасьютикалз, Инк. Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
RU2020120797A (ru) 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
AU2017340816C1 (en) * 2016-10-04 2022-02-10 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
JP2020514365A (ja) * 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
EP4216979A4 (en) * 2020-09-24 2024-11-06 Rhythm Pharmaceuticals, Inc. Methods of treating melanocortin-4 receptor pathway-associated disorders
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
CN120192363A (zh) * 2023-12-22 2025-06-24 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE109793T1 (de) * 1987-05-22 1994-08-15 University Patents Inc Lineare und zyklische analoge von alpha-msh- fragmenten mit ausserordentlicher wirkung.
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
CZ2003584A3 (cs) * 2000-08-30 2003-08-13 F. Hoffmann-La Roche Ag Selektivní cyklické peptidy
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
WO2005000338A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CA2530024A1 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
PL2286825T3 (pl) 2005-07-08 2017-06-30 Ipsen Pharma Ligandy receptora melanokortyny
JP2009500426A (ja) 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
ES2618315T3 (es) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Ligandos del receptor de melanocortina modificados con hidantoína
AR066175A1 (es) 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
NZ585131A (en) 2007-11-05 2012-10-26 Ipsen Pharma Sas Use melanocortins to treat insulin sensitivity
TW201002340A (en) * 2008-06-09 2010-01-16 Palatin Technologies Inc Melanocortin receptor-specific peptides for treatment of obesity
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
KR101726893B1 (ko) 2009-06-08 2017-04-13 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴 수용체-특이적 펩티드
BR112012002445A2 (pt) * 2009-08-05 2015-10-13 Ipsen Pharma Sas uso de um agonista do receptor 4 de melanocortina.
US9314509B2 (en) 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
CA2833676C (en) 2011-06-14 2019-04-23 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as active ingredient
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
PL2970389T3 (pl) 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2785889C1 (ru) * 2015-09-30 2022-12-14 Ритм Фармасьютикалз, Инк. Способ лечения нарушений, ассоциированных с путем рецептора меланокортина 4

Also Published As

Publication number Publication date
EP3450449A3 (en) 2019-06-12
EP3450449A2 (en) 2019-03-06
JP2025102830A (ja) 2025-07-08
HK1220697A1 (en) 2017-05-12
JP2016516719A (ja) 2016-06-09
US10196425B2 (en) 2019-02-05
ES2693761T3 (es) 2018-12-13
AU2021269411A1 (en) 2021-12-16
JP7654587B2 (ja) 2025-04-01
US10858399B2 (en) 2020-12-08
RU2725150C2 (ru) 2020-06-30
US20250188124A1 (en) 2025-06-12
CN118240012A (zh) 2024-06-25
WO2014144260A1 (en) 2014-09-18
JP2022084844A (ja) 2022-06-07
US12077612B2 (en) 2024-09-03
US20190092815A1 (en) 2019-03-28
TR201815173T4 (tr) 2018-11-21
US20210040155A1 (en) 2021-02-11
AU2020203353A1 (en) 2020-06-11
JP2019172693A (ja) 2019-10-10
RU2020120797A (ru) 2020-07-02
AU2014227712A1 (en) 2015-10-01
EP2970388B1 (en) 2018-07-25
EP2970388A1 (en) 2016-01-20
RU2015145593A (ru) 2017-04-24
JP6622690B2 (ja) 2019-12-18
AU2024200528A1 (en) 2024-02-15
AU2018256493A1 (en) 2018-11-22
US20160017001A1 (en) 2016-01-21
CN105492456A (zh) 2016-04-13
CN118271400A (zh) 2024-07-02
CN105492456B (zh) 2024-11-01
AU2014227712B2 (en) 2018-08-02
JP7046871B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
US12077612B2 (en) Peptide compositions
AU2019200101B2 (en) Pharmaceutical Compositions
EP3356386B1 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
HK40006194A (en) Peptide compositions
HK1220697B (en) Peptide compositions
HK1220702B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190314

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20240820

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250314

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250314

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250314

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250828

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250828

P12 Request for amendment of application rejected

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P12-P147 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REJECTED AMENDMENT AFTER RCE - PREVIOUSLY ACCEPTED AMENDMENT AFTER ALLOWANCE REJECTED

Effective date: 20250828

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250828

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250828

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251014